Stock comparison
Mettler-Toledo International
BeOne Medicines
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
MTD
Mettler-Toledo International
Market cap
$22.29B
Sector
Healthcare
ONC
BeOne Medicines
Market cap
$33.15B
Sector
Healthcare
Overall winner
Mettler-Toledo International MTD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | MTD | ONC | Winner |
|---|---|---|---|
| Warren Buffett | 69B | 62D | MTD |
| Benjamin Graham | 65B | 75D | ONC |
| Philip Fisher | 63C | 84C | ONC |
| Peter Lynch | 66B | 75B | ONC |
| Joel Greenblatt | 68B | 49D | MTD |
| Charlie Munger | 74B | 56D | MTD |
| Terry Smith | 70B | 60D | MTD |
Side-by-side metrics
| Metric | MTD | ONC |
|---|---|---|
| Market cap | $22.29B | $33.15B |
| P/E (TTM) | 25.3x | 107.5x |
| EV/EBIT | 21.6x | 28.9x |
| ROIC (TTM) | 36.09% | 7.73% |
| Gross margin | 57.79% | 87.17% |
| Net margin | 21.4% | 8.93% |
| Revenue CAGR 5y | 2.01% | 45.99% |
| EPS CAGR 5y | 6.12% | 67.36% |
| Debt / Equity | - | 0.4x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
MTD leads on
- Debt / Equity-vs 0.4x+101%
- ROIC (TTM)36.09%vs 7.73%+79%
- P/E (TTM)25.3xvs 107.5x+76%
- Net margin21.4%vs 8.93%+58%
ONC leads on
- Revenue CAGR 5y45.99%vs 2.01%+96%
- EPS CAGR 5y67.36%vs 6.12%+91%
- Gross margin87.17%vs 57.79%+34%
- Market cap$33.15Bvs $22.29B+33%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.